Vol. 20/No. 12 | OncologyLive

Investigators Express Confidence in a Novel TKI That Targets Rare Sarcomas

June 26, 2019

Anlotinib, a novel tyrosine kinase inhibitor capable of mounting a multipronged attack against oncogenic processes, is being tested in rare soft tissue sarcoma subtypes where patients have limited therapeutic options.

New Approaches Are Shifting the Landscape in Immune Thrombocytopenia

June 24, 2019

During a recent OncLive Peer Exchange discussion, a trio of immune thrombocytopenia specialists review clinical trial data that led to approval of the second-line agents, talk about efforts to refine first-line treatment, and discuss how they approach therapy selection for refractory patients. Finally, they highlight emerging therapies for ITP and the need to expand the pipeline.

University of Wisconsin Team Develops Novel Strategy for High-Risk Neuroblastoma

June 20, 2019

Investigators at the University of Wisconsin American Family Children’s Hospital are developing a new approach to treating patients with neuroblastoma that has the potential to improve outcomes for patients whose disease has not responded to conventional therapy.

PSMA Emerges as Versatile Target in Prostate Cancer and Beyond

June 19, 2019

Named the medical invention of the Year by TIME magazine at the turn of the millennium, positron emission tomography/computed tomography has changed the landscape of cancer diagnosis, facilitating earlier detection and more accurate staging of a range of tumor types.

The Fight to Save the Bladder Turns to Genomics

June 14, 2019

The search for effective alternatives to radical cystectomy (RC) in patients with bladder cancer has lasted more than 3 decades. Progress has been slow, but investigators have proved that a combination of radiation, chemotherapy, and maximal transurethral resection of the bladder tumor works as well as RC in carefully selected patients.